
BIOGRAPHICAL SKETCH

Davide Melisi, MD, PhD

Full Professor of Medical Oncology
Digestive Molecular Clinical Oncology Research Unit, Head
University of Verona - Division of Medical Oncology
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
CENTRO RICERCHE CLINICHE DI VERONA s.r.l.

Piazzale L.A.Scuro, 10
37134, Verona, Italy

Present Position

From 1 July 2021	Director of the UOS of Experimental Therapies in Oncology AOUI Verona
From 10 November 2020	Full Professor at the Medical Oncology Unit of the University of Verona - Sector: MED/06 MEDICAL ONCOLOGY - Competition Sector: 06/D3
From 1 October 2018	Assistant Professor at the Medical Oncology Unit of the University of Verona - Sector: MED/06 MEDICAL ONCOLOGY - Competition Sector: 06/D3 - Head of the research unit of Oncology Molecular Clinical Digestive System, University of Verona

Dr. Melisi has been directly involved in laboratory and clinical research since his internship as MD student and as fellow in Medical Oncology at the Division of Medical Oncology and the Laboratory of Molecular Cancer Therapy of the University of Naples "Federico II" Medical School.

In 2005, he joined the Department of Gastrointestinal Medical Oncology at the MD Anderson Cancer Center Houston, TX. Here, he was involved in different translational research projects on the role of targeting signal transduction molecules on the development, growth, and metastatization of pancreatic cancer. In particular, he focused his work on the inhibition of the Smad-dependent and Smad-independent pathways driven by the Transforming Growth Factor β as therapeutic strategies in pancreatic cancer. In the same period, he was engaged in the clinical design and pharmacodynamic analyses of several phase I and II clinical trials in pancreatic and biliary cancers. During his postdoctoral training, Dr. Melisi was supported by several competitive fellowships through the Italian Foundation for Cancer Research, the American-Italian Cancer Foundation, and the SASS Foundation for Medical Research, and selected to attend several competitive courses, including the 2007 NCI-AACR Cancer Research Imaging Camp at the Center for In Vivo Microscopy, Duke University, Durham, NC, and the 2008 Methods in Clinical Cancer Research AACR/ASCO Workshop, Vail, CO.

In 2009, Dr. Melisi was recruited as Clinical and Experimental Tenure Lecturer at the National Cancer Institute – Fondazione G. Pascale in Naples, Italy. In 2010, he received his PhD degree in Molecular Oncology and Endocrinology, University of Naples "Federico II", Italy.

In December 2011, he finally joined the University of Verona, Italy, as Assistant Professor of Medical Oncology.

In 2011, Dr. Melisi was awarded one of the prestigious and highly competitive Start-Up program grants, the largest funding for cancer research in my country *"to foster the birth and growth of new research units under the leadership of talented young scientists seeking the opportunity of becoming independent investigators in Italy after a successful research experience abroad"* through the Italian Association for Cancer Research (AIRC).

Thanks to this 5-years research grant, Dr. Melisi established the Digestive Molecular Clinical Oncology (DMCO) Research Unit. In his research unit, he coordinate and supervise the work of three postdoctoral fellows, one graduated PhD student, one research assistant, one research nurse, and

four students. The main projects in his group are aimed to define the tumor cell-autonomous and tumor microenvironment- related molecular mechanisms responsible for the resistance of pancreatic cancer to the proapoptotic activity of the classic chemotherapeutic agents and to the most novel antiangiogenic drugs.

At the Verona University Hospital, Dr. Melisi is responsible for the gastrointestinal tumor patients' clinic. In particular, he participates as medical oncologist to the *Pancreas Centre*, the most important multidisciplinary team in the country for the diagnosis, treatment and research of the diseases of the pancreas. In collaboration with the early phase clinical trials unit Centro di Ricerche Cliniche (CRC), he is in charge of the cancer therapeutics' early phase clinical development program accordingly with GCP guidelines.

Dr. Melisi serve as the coordinator of the School of Specialty in Medical Oncology. Here, he organize classes and practical activities of twenty-five fellows per year, and directly supervise the clinical and research work of five of them. Dr. Melisi is teacher of Medical Oncology for the University of Verona's Medical School, and the Schools of Specialty in Oncology, Surgery, and Gastroenterology. He am also member of the board of the PhD program in Molecular Pathology, Immunology, and Oncology.

Beside the AIRC Start-Up grant, Dr. Melisi have been awarded as principal investigator or co-investigator several national and international competitive research grants from private charities and pharmaceutical industries. Dr. Melisi received several prestigious awards, including the 2003 "Prof. Piero Trivella" award from Italian Cancer Society, the 2007 "The Marion D. Edwards" award in Hepatic Oncology, and the 2008 "Nunzio Pascale" International award for cancer research. Dr. Melisi is member of the editorial board of the journal of the European Society of Medical Oncology *Annals of Oncology*, and he routinely serve as reviewer for several other peer-reviewed journals. In 2013, Dr Melisi has been elected member of the Board of the Italian Cancer Society (SIC).

Education and degrees

2001	MD Degree, Summa cum Laude, University of Naples "Federico II" Medical School, Italy
2005	Specialty Degree in Medical Oncology, Summa cum Laude, University of Naples "Federico II", Italy
2009	PhD Degree, International Doctorate Program in Molecular Oncology and Endocrinology, University of Naples "Federico II", Italy

Medical Licence Registration

17/02/2003 - Albo Provinciale dei Medici Chirurghi di NAPOLI (Ordine della Provincia di NAPOLI) n. 0000030080

Professional Experience/Other Related Training

2001-2005	Resident/Fellow, Internal Medicine/Medical Oncology, Division of Medical Oncology, University of Naples "Federico II" Medical School, Italy
2005-2009	Postdoctoral Fellow, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center – University of Texas, Houston, TX, US
2009-2011	Clinical and Experimental Tenure Lecturer, National Cancer Institute – Fondazione G. Pascale, Naples, Italy
2011-present	Assistant Professor, Department of Medical Oncology, University of Verona, Italy
2011-present	Head, Digestive Molecular Clinical Oncology Research Unit, University of Verona, Italy

Honors

2003	"Prof. Piero Trivella" award, Italian Cancer Society (SIC), Italy
2005	"Leonino Fontana e Maria Lionello" award, Italian Foundation for Cancer Research (FIRC), Italy
2007	"The Marion D. Edwards" award in Hepatic Oncology, MD Anderson Cancer Center, Houston, TX, US
2007	Fellow at the NCI-AACR Cancer Research Imaging Camp, Duke University, Center for In Vivo Microscopy, Durham, NC
2008	"Nunzio Pascale" International award for cancer research – "Nunzio Pascale" Foundation, Italy
2008	The SASS Foundation for Medical Research Postdoctoral Research Fellowship, Roslyn, NY, US
2008	American-Italian Cancer Foundation Postdoctoral Research Fellowship, New York, NY, US
2008	Fellow at the Methods in Clinical Cancer Research AACR/ASCO Workshop, Vail, CO

Since 2005 Involved, as sub-I and Primary Investigator, in several international clinical trials conducted according to GCP

Training Documentation

TRANSCCELERATE - ICH GCP E6 (R2) Training E-Learning Course on 08 October 2020

Ongoing Research Support

AIRC Start-Up Grant n. 10129, 2010-2015, Role: PI

Mechanisms of resistance to chemotherapeutic and antiangiogenic drugs as targets for pancreatic cancer therapy – Associazione Italiana per la Ricerca sul Cancro

AIRC Special Program Molecular Clinical Oncology 5 per mille n. 10016, Role: participating unit

Molecular basis for triple negative breast cancer metastasis: new tools for diagnosis and therapy – Associazione Italiana per la Ricerca sul Cancro

Peer-reviewed publications

1. Tortora G, Caputo R, Damiano V, Fontanini G, **Melisi D**, Veneziani BM, Zunino F, Bianco AR, Ciardiello F. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res. 2001 7(12): 4156-63.
2. Tortora G, Caputo R, Damiano V, **Melisi D**, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003 9(4): 1566-72.
3. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, **Melisi D**, De Vita F, De Placido S, Bianco AR, Tortora G. Antitumor Activity of ZD6474, a VEGFR Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Anti-EGFR Therapy. Clin Cancer Res. 2004 10(2): 784-793.
4. Tortora G, **Melisi D** and Ciardiello F. Angiogenesis: A Target for Cancer Therapy. Curr Pharm Des. 2004 10(1): 11-26.
5. Raben D, Bianco C, Damiano V, Bianco R, **Melisi D**, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase

inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. *Mol Cancer Ther*. 2004 3(8): 977-83.

6. **Melisi D**, Troiani T, Damiano V, Tortora G and Ciardiello F. Therapeutic integration of signal transduction targeting agents and conventional anti- cancer treatments. *Endocr Relat Cancer*. 2004 11(1): 51-68.
7. Damiano V, **Melisi D**, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. *Clin Cancer Res*. 2005 11(15): 5639-44.
8. **Melisi D**, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F and Tortora G. Zoledronic acid cooperates with a COX-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. *Endocr Relat Cancer*. 2005 12(4):1051-8.
9. Bianco R, **Melisi D**, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. *Eur J Cancer*. 2006 42(3):290
10. **Melisi D**, Chiao PJ. NF-kappaB as a target for cancer therapy. *Expert Opin Ther Targets*. 2007 Feb;11(2):133-44.
11. **Melisi D**, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. LY2109761, a Novel Transforming Growth Factor β Receptor type I and II dual inhibitor, as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis. *Mol Cancer Ther*. 2008 Apr;7(4):829-40.
12. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, **Melisi D**, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. *Clin Cancer Res*. 2008 Aug 15;14(16):5069-80.
13. **Melisi D**, Niu J, Chang Z, Ishiyama S, Peng B, Xia Q, Evans DB, and Chiao PJ. Secreted Interleukin-1 α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of NF- κ B. *Mol Cancer Res*. 2009 May;7(5):624-33.
14. **Melisi D**, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL, Chiao PJ. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. *Clin Cancer Res*. 2009 Oct 5;15(20):6367-77.
15. Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao P, Abbruzzese JL, and **Melisi D**. Anti-VEGF Treatment Resistant Pancreatic Cancers Secrete Proinflammatory Factors that Contribute to Malignant Progression by Inducing an EMT cell phenotype. *Clin Cancer Res*. 2011 Sep 1;17(17):5822-32. IF
16. **Melisi D**, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ. Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. *J Natl Cancer Inst*. 2011 Aug 3;103(15):1190-204.
17. Vaccaro V*, **Melisi D***, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. *Expert Opin Ther Targets*. 2011 Oct;15(10):1183-96. *CFA
18. Rosa R, **Melisi D**, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-Ras mutant colorectal and pancreatic cancers. *Clin Cancer Res*. 2011 Oct 15;17(20):6531-41.
19. Carbone C, and **Melisi D**. NF-kappaB as a target for pancreatic cancer therapy. *Expert Opin Ther Targets*. 2012 Apr;16 Suppl 2:S1-10.
20. **Melisi D**, Budillon A. Editorial: pancreatic cancer: between bench and bedside. *Curr Drug Targets*. 2012 Jun 1;13(6):729-30.
21. Tamburrino A, Piro G, Carbone C, Tortora G, and **Melisi D**. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. *Front*

Pharmacol. 2013 Apr 30;4:56.

22. **Melisi D**, Piro G, Tamburrino A, Carbone C, Tortora G. Rationale and clinical use of multitargeting anticancer agents. *Curr Opin Pharmacol*. 2013 Aug;13(4):536-42.
23. Lucchini E, Pilotto S, Spada E, **Melisi D**, Bria E, Tortora G. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. *Expert Opin Drug Saf*. 2014 May;13(5):535-49.
24. Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, **Melisi D**, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. *Oncotarget*. 2014 May 15;5(9):2839-52.
25. **Melisi D**, Calveti L, Frizziero M, Tortora G. Pancreatic cancer: systemic combination therapies for a heterogeneous disease. *Curr Pharm Des*. 2014;20(42):6660-9.
26. Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanotto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, and **Melisi D**. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. *Oncotarget*. 2014 Oct 24. pii: 2635.
27. Dalla Pozza E, Dando I, Biondani G, Brandi J, Costanzo C, Zoratti E, Fassan M, Boschi F, **Melisi D**, Cecconi D, Scupoli MT, Scarpa A, Palmieri M. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. *Int J Oncol*. 2015 Mar;46(3):1099-108.
28. Vaccaro V, Sperduti I, Vari S, Bria E, **Melisi D**, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? *World J Gastroenterol*. 2015 Apr 28;21(16):4788-801.
29. Piro G, Giacomuzzi S, Bencivenga M, Carbone C, Verlato G, Frizziero M, Zanotto M, Mina MM, Merz V, Santoro R, Zanoni A, De Manzoni G, Tortora G, and **Melisi D**. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. *Br J Cancer*. 2015 Sep 15;113(6):878-85.
30. Simionato F, Frizziero M, Carbone C, Tortora G, and **Melisi D**. Current strategies to overcome resistance to ALK-inhibitor agents. *Curr Drug Metab*. 2015 Aug 12.
31. Carbone C, Tamburrino A, Piro G, Boschi F, Cataldo I, Zanotto M, Mina MM, Zanini S, Sbarbati A, Scarpa A, Tortora G, and **Melisi D**. Combined inhibition of IL1, CXCR1/2, and TGF β signaling pathways modulates in vivo resistance to anti-VEGF treatment. *Anticancer Drugs*. 2015 Oct 15
32. Zhuang Z, Ju H, Aguilar M, Gocho T, Li H, Iida T, Lee H, Fan X, Zhou H, Ling J, Li Z, Fu J, Wu M, Li M, **Melisi D**, Iwakura Y, Xu K, Fleming JB, Chiao PJ. IL-1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF- κ B Activation. *Clin Cancer Res*. 2015 Oct 23. [Epub ahead of print]
33. Brannon AR, Frizziero M, Chen D, Hummel J, Gallo J, Riester M, Patel P, Cheung W, Morrissey M, Carbone C, Cottini S, Tortora G, and **Melisi D**. Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001. *Cold Spring Harb Mol Case Stud*, Published in Advance December 29, 2015 doi:10.1101/mcs.a000620
34. Zhuang Z, Ju H, Aguilar M, Gocho T, Li H, Iida T, Lee H, Fan X, Zhou H, Ling J, Li Z, Fu J, Wu M, Li M, **Melisi D**, Iwakura Y, Xu K, Fleming JB, Chiao PJ. IL-1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF- κ B Activation. *Clin Cancer Res*. 2016 Mar 15;22(6):1432-44.
35. Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Gionmonni E, Fornaro L, Aprile G, **Melisi D**, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016 Dec 15;139(12):2859-2864.

36. Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacomuzzi S, Aprile G, Simionato F, Boschi F, Zanutto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, and **Melisi D**. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. *Clin Cancer Res*. 2016 Jun 7.
37. Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, Casolino R, Santoro R, Mina MM, Zecchetto C, Merz V, Scarpa A, Bassi C, Tortora G, and **Melisi D**. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. *Oncoimmunology*. 2017 Apr 28;6(9):e1322242.
38. Pelzer U, Blanc JF, **Melisi D**, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. *Br J Cancer*. 2017 May 9;116(10):1247-1253.
39. Humphries MP, Sundara Rajan S, Droop A, Suleman C, Carbone C, Nilsson C, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Walker RA, Kulka J, Ellis IO, Jeffery M, Thygesen HH, Cappelletti V, Daidone MG, Hedenfalk IA, Fjällskog ML, **Melisi D**, Stead L, Shaaban A, Speirs V. A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer. *Clin Cancer Res*. 2017 May 15;23(10):2575-2583.
40. Aprile G, Negri FV, Giuliani F, De Carlo E, **Melisi D**, Francesca Simionatoe, Nicola Silvestrisd, Oronzo Brunettid, Francesco Leonef, Donatella Marinof, Daniele Santinig, Emanuela Dell'Aquilag, Tea Zeppola, Marco Puzzonei, Mario Scartozzi. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? *Crit Rev Oncol Hematol*. 2017 Jul;115:1-12.
41. Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Alì G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanutto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, and **Melisi D**. Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients. *Clin Cancer Res*. 2017 Aug 1;23(15):4312-4322.
42. Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, **Melisi D**, Antonuzzo L, Pellegrino A, Torri V, Aprile G. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. *Gastric Cancer*. 2017 Sep;20(5):825-833.
43. Gaianigo N, **Melisi D**, Carbone C. EMT and Treatment Resistance in Pancreatic Cancer. *Cancers (Basel)*. 2017 Sep 12;9(9).
44. Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Donato SD, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, **Melisi D**, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. *Future Oncol*. 2017 Oct;13(25):2265-2275.
45. Federti E, Matte' A, Ghigo A, Andolfo I, James C, Siciliano A, Leboeuf C, Janin A, Manna F, Choi SY, Iolascon A, Beneduce E, **Melisi D**, Kim DW, Levi S, De Franceschi L. Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. *Free Radic Biol Med*. 2017 Nov;112:376-386.
46. Federti E, Matte A, Ghigo A, Andolfo I, James C, Siciliano A, Leboeuf C, Janin A, Manna F, Choi SY, Iolascon A, Beneduce E, **Melisi D**, Kim DW, Levi S, De Franceschi L. Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. *Data Brief*. 2017 Sep 30;15:376-381
47. Santoro R, Carbone C, Piro G, Chiao PJ, **Melisi D**. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. *Drug Resist Updat*. 2017 Nov;33-35:36-42.

48. Matte A, De Falco L, Federti E, Cozzi A, Iolascon A, Levi S, Mohandas N, Zamo A, Bruno M, Leboeuf C, Janin A, Siciliano A, Ganz T, Federico G, Carlomagno F, Mueller S, Silva I, Carbone C, **Melisi D**, Kim DW, Choi SY, DE Franceschi L. Peroxiredoxin-2: a novel regulator of iron homeostasis in ineffective erythropoiesis. *Antioxid Redox Signal*. 2018 Jan 1;28(1):1-14.
49. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, **Melisi D**, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist*. 2017 Dec;22(12):1463-1469.
50. Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G, **Melisi D**. Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. *Int J Mol Sci*. 2018 Feb 1;19(2).
51. Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, **Melisi D**. The development of PARP as a successful target for cancer therapy. *Expert Rev Anticancer Ther*. 2018 Feb;18(2):161-175.
52. Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, De Franceschi L, Scarpa A, Tortora G, **Melisi D**. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. *Int J Obes (Lond)*. 2018 Mar;42(3):334-343.
53. Innamorati G, Wilkie TM, Kantheti HS, Valenti MT, Dalle Carbonare L, Giacomello L, Parenti M, **Melisi D**, Bassi C. The curious case of Gαs gain-of-function in neoplasia. *BMC Cancer*. 2018 Mar 15;18(1):293.
54. Piro G, Carbone C, Santoro R, Tortora G, **Melisi D**. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. *Expert Rev Mol Diagn*. 2018 Mar 16.
55. Santoro R, Zanutto M, Carbone C, Piro G, Tortora G, **Melisi D**. MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. *Anticancer Res*. 2018 Apr;38(4):1937-1946.
56. Paiella S, Salvia R, De Pastena M, Pollini T, Casetti L, Landoni L, Esposito A, Marchegiani G, Malleo G, De Marchi G, Scarpa A, D'Onofrio M, De Robertis R, Pan TL, Maggino L, Andrianello S, Secchettin E, Bonamini D, **Melisi D**, Tuveri M, Bassi C. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. *Pancreatology*. 2018 Apr 10. pii: S1424-3903(18)30068-1.
57. Trestini I, Carbognin L, Sperduti I, Bonaiuto C, Auriemma A, **Melisi D**, Salvatore L, Bria E, Tortora G. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. *Eur J Clin Nutr*. 2018 May;72(5):772-779.
58. Ciaravino V, Cardobi N, DE Robertis R, Capelli P, **Melisi D**, Simionato F, Marchegiani G, Salvia R, D'Onofrio M. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. *Anticancer Res*. 2018 Aug;38(8):4889-4895. doi: 10.21873/anticancerres.12803.
59. **Melisi D**, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Tabernero J. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. *Br J Cancer*. 2018 Oct 15.
60. Cascetta P, Cavaliere A, Piro G, Torroni L, Santoro R, Tortora G, **Melisi D**, Carbone C. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. *Int J Mol Sci*. 2018 Oct 25;19(11).
61. Marchegiani G, Andrianello S, Dal Borgo C, Secchettin E, **Melisi D**, Malleo G, Bassi C, Salvia R. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of

invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. *HPB (Oxford)*. 2018 Oct 23.

62. Hubner RA, Cubillo A, Blanc JF, **Melisi D**, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. *Eur J Cancer*. 2018 Nov 17;106:24-33.

63. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, **Melisi D**, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biciato S, Blazar BR, Sahin U, Murray PJ, Bronte V. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat Commun*. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4.

64. Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, **Melisi D**, Vasile E, Gerratana L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol*. 2018 Dec 11.

65. **Melisi D**, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J. TGF β receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. *Cancer Chemother Pharmacol*. 2019 May;83(5):975-991.

66. Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, **Melisi D**, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. *JAMA Surg*. 2019 Jul 24. doi: 10.1001/jamasurg.2019.2277.

67. Gueorguieva I, Tabernero J, **Melisi D**, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor- β inhibitor galunisertib in patients with pancreatic cancer. *Cancer Chemother Pharmacol*. 2019 Nov;84(5):1003-1015.

68. Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Trisciuglio D, Iuliano A, Del Bufalo D, Di Bernardo D, **Melisi D**, Draetta GF, Ciliberto G, Carugo A, Cardone L. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. *Cancer Res*. 2019 Nov 1;79(21):5612-5625.

69. Santoro R, Zanutto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, **Melisi D**. Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer. *Mol Cancer Ther*. 2019 Sep 27.

70. Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, **Melisi D**. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. *J Gastric Cancer*. 2019 Dec;19(4):375-392. doi: 10.5230/jgc.2019.19.e39. Epub 2019 Nov 13.

71. Taieb J, Prager GW, **Melisi D**, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. *ESMO Open*. 2020 Jan;5(1).

72. Park SY, Matte A, Jung Y, Ryu J, Wilson AB, Han EYA, Liu M, Carbone C, **Melisi D**, Nagasawa T, Locascio JJ, Lin CP, Silberstein LE, De Franceschi L. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion. *Blood*. 2020 Jan 27. pii: blood.2019002227. doi: 10.1182/blood.2019002227.

73. Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, **Melisi D**, Scarpa A, Ciuffreda L, Milella M, Cognetti F. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. *Cells*. 2020 Jan 28;9(2).
74. Caccialanza R, Cereda E, Klersy C, Brugnatelli S, Borioli V, Ferrari A, Caraccia M, Lobascio F, Pagani A, Delfanti S, Aprile G, Reni M, Rimassa L, **Melisi D**, Cascinu S, Battistini L, Candiloro F, Pedrazzoli. Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. *Ther Adv Med Oncol*. 2020 Feb 22;12:1758835919890281.
75. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, **Melisi D**, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2020 Mar 20. pii: S1470-2045(20)30109-1. doi: 10.1016/S1470-2045(20)30109-1.
76. De Robertis R, Beleù A, Cardobi N, Frigerio I, Ortolani S, Gobbo S, Maris B, **Melisi D**, Montemezzi S, D'Onofrio M. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. *Abdom Radiol (NY)*. 2020 Apr 7. doi: 10.1007/s00261-020-02509-3.
77. Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, Milella M, Caffo O, **Melisi D**. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. *Cancers (Basel)*. 2020 Apr 30;12(5):1131.
78. Trestini I, Paiella S, Sandini M, Sperduti I, Elio G, Pollini T, **Melisi D**, Auriemma A, Soldà C, Bonaiuto C, Tregnago D, Avancini A, Secchettin E, Bonamini D, Lanza M, Pilotto S, Malleo G, Salvia R, Bovo C, Gianotti L, Bassi C, Milella M. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. *Ann Surg Oncol*. 2020 May 9.
79. Fedele V, **Melisi D**. Permissive State of EMT: The Role of Immune Cell Compartment. *Front Oncol*. 2020 Apr 22;10:587.
80. Lupo F, Piro G, Torroni L, Delfino P, Trovato R, Rusev B, Fiore A, Filippini D, De Sanctis F, Manfredi M, Marengo E, Lawlor RT, Martini M, Tortora G, Ugel S, Corbo V, **Melisi D**, Carbone C. Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. *Front Cell Dev Biol*. 2020 Apr 28;8:308.
81. Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, and **Melisi D**. Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer. *Clin Cancer Res*. 2020. DOI: 10.1158/1078-0432.CCR-20-0395
82. Zuliani S, Zampiva I, Tregnago D, Casali M, Cavaliere A, Fumagalli A, Merler S, Riva ST, Rossi A, Zacchi F, Zaninotto E, Auriemma A, Pavarana M, Soldà C, Benini L, Borghesani M, Caldart A, Casalino S, Gaule M, Kadrija D, Mongillo M, Pesoni C, Biondani P, Cingarlini S, Fiorio E, **Melisi D**, Parolin V, Tondulli L, Belluomini L, Zecchetto C, Avesani B, Biasi A, Bovo C, Dazzani E, Dodi A, Gelmini S, Leta LC, Lo Cascio G, Lombardo F, Lucin E, Martinelli IA, Messineo L, Moscarda V, Pafumi S, Reni A, Sartori G, Scaglione IM, Shoval Y, Sposito M, Tacconelli E, Trestini I, Zambonin V, Zanelli S, Pilotto S, Milella M. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. *Eur J Cancer*. 2020 Jun 11;135:159-169.
83. Bekaii-Saab TS, Valle JW, Cutsem EV, Rimassa L, Furuse J, Ioka T, **Melisi D**, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. *Future Oncol*. 2020 Jul 17.
84. Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacomuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M,


- Piazzola C, Milleri S, de Manzoni G, **and Melisi D**. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. *Ther Adv Med Oncol*. 2020 Jul 7 ;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020.
85. Simionato F, Zecchetto C, Merz V, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuveri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbriellini A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, and **Melisi D**. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. *Ther Adv Med Oncol*. 2020 Sep 4;12:1758835920947969.
86. Merz V, Zecchetto C, **and Melisi D**. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. *Future Oncol*. 2020 Oct 9.
87. Luchini C, Paolino G, Mattiolo P, Piredda ML, Cavaliere A, Gaule M, **Melisi D**, Salvia R, Malleo G, Shin JI, Cargnin S, Terrazzino S, Lawlor RT, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *J Exp Clin Cancer Res*. 2020 Oct 28;39(1):227.
88. Contarelli S, Fedele V, **Melisi D**. HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. *Cancers (Basel)*. 2020 Nov 8;12(11):E3299.
89. Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H, Feliz L, Zecchetto C, **Melisi D**, Burn TC. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. *Cancer Discov*. 2020 Nov 20:CD-20-0766.
90. Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, **Melisi D**, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. *ESMO Open*. 2021 Jan 4;6(1):100032.
91. Carrato A, **Melisi D**, Prager G, Westphalen CB, Ferreras A, D'Esquermes N, Taieb J, Mercadé TM. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. *Future Oncol*. 2021 Mar 5.
92. **Melisi D**, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. *J Immunother Cancer*. 2021 Mar;9(3):e002068.
93. Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, and **Melisi D**. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. *Front Oncol*. 2021 Mar 11;11:638360.
94. **Melisi D**, Cavaliere A, Gobbo S, Fasoli G, Allegrini V, Simionato F, Gaule M, Casalino S, Pesoni C, Zecchetto C, Merz V, Mambrini A, Barbi E, Girelli R, Giardino A, Frigerio I, Scalapogna R, Avitabile A, Castellani S, Milella M, Butturini G. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. *Pancreatol*. 2021 Apr 19:S1424-3903(21)00143-5.
95. Pietrobono S, and **Melisi D**. A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib. *Cell Mol Gastroenterol Hepatol*. 2021 Jun 25:S2352-345X(21)00120-X.
96. Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, **Melisi D**, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, Cohen G. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. *Oncol Ther*. 2021 Jul 10.

96. Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, **Melisi D**, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, Cohen G. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. *Oncol Ther*. 2021 Jul 10.
97. Sabbadini F, Bertolini M, De Matteis S, Mangiameli D, Contarelli S, Pietrobono S, **Melisi D**. The Multifaceted Role of TGF- β in Gastrointestinal Tumors. *Cancers (Basel)*. 2021 Aug 5;13(16):3960.
98. Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, and **Melisi D**. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer. *Clin Cancer Res*. 2021 Sep 21;clincanres.1504.2021. doi: 10.1158/1078-0432.CCR-21-1504.
99. Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. *Expert Rev Gastroenterol Hepatol*. 2021

I authorize the treatment of my data according to the applicable local regulation about data protection and any further amendments



Davide Melisi, MD, Ph.D.



date (dd/mm/yyyy)